Alpha 2.0
Login Register
» Authors » Omar Dabbous

Omar Dabbous

Explore the profile of Omar Dabbous including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 45
Citations 1489
Followers 0
Related Specialties
Public Health
Pharmacology
General Medicine
Top 10 Co-Authors
Walter Toro
Anish Patel
Mondher Toumi
Sean D Sullivan
Bhavik J Pandya
Eswar Krishnan
Benit Maru
Daniel C Malone
Douglas M Sproule
Sean Tunis
Published In
Adv Ther
J Mark Access Health Policy
Value Health
Dig Dis Sci
Arthritis Res Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Evolving Concept of Value in Health Economics and Outcomes Research: Emerging Tools for Innovation and Access to Cell and Gene Therapies for Rare Diseases
Toro W, Yang M, Patel A, Zhang S, Dabbous O, Garrison Jr L, et al.
Value Health . 2025 Jan; PMID: 39743177
Objectives: Recent scientific breakthroughs have propelled the development of disease-modifying and potentially curative cell and gene therapies (CGTs) for rare diseases, including those diseases previously considered untreatable. The unique characteristics...
2.
Risdiplam utilization, adherence, and associated health care costs for patients with spinal muscular atrophy: a United States retrospective claims database analysis
Patel A, Toro W, Yang M, Song W, Desai R, Ye M, et al.
Orphanet J Rare Dis . 2024 Dec; 19(1):494. PMID: 39736792
Background: Spinal muscular atrophy (SMA) is a genetic neuromuscular disease associated with progressive loss of motor function. Risdiplam, a daily oral therapy, was approved in the United States for the...
3.
Treatment preferences in spinal muscular atrophy: A swing weighting study for caregivers of patients with SMA types 1 and 2
Patel A, Toro W, Bourke S, Oluboyede Y, Barbier S, Bogoeva N, et al.
PLoS One . 2024 Oct; 19(10):e0309666. PMID: 39432490
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by skeletal muscle weakness and atrophy. Patients with SMA types 1 and 2 develop severe disabilities conferring substantial patient and...
4.
Real-world evidence for coverage determination of treatments for rare diseases
Dayer V, Drummond M, Dabbous O, Toumi M, Neumann P, Tunis S, et al.
Orphanet J Rare Dis . 2024 Feb; 19(1):47. PMID: 38326894
Health technology assessment (HTA) decisions for pharmaceuticals are complex and evolving. New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence...
5.
A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies
Saleh S, Dabbous O, Sullivan S, Ankleshwaria D, Trombini D, Toumi M, et al.
Gene Ther . 2023 Oct; 31(1-2):1-11. PMID: 37903929
In the rapidly evolving landscape of biotechnologies, cell and gene therapies are being developed and adopted at an unprecedented pace. However, their access and adoption remain limited, particularly in low-...
6.
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey
Toro W, Yang M, Georgieva M, Anderson A, LaMarca N, Patel A, et al.
Adv Ther . 2023 Sep; 40(12):5315-5337. PMID: 37776479
Introduction: Onasemnogene abeparvovec (OA) is the only gene replacement therapy currently approved for spinal muscular atrophy (SMA) treatment. We sought to assess real-world patient and caregiver outcomes after OA treatment...
7.
Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis
Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang A, et al.
Adv Ther . 2023 Aug; 40(10):4589-4605. PMID: 37587305
Introduction: Spinal muscular atrophy (SMA) is a neurogenic disorder associated with progressive loss of muscle function, respiratory failure, and premature mortality. This study aimed to describe and compare real-world health...
8.
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal
Toumi M, Dabbous O, Aballea S, Drummond M, von der Schulenburg J, Malone D, et al.
Expert Rev Pharmacoecon Outcomes Res . 2023 Apr; 23(5):483-497. PMID: 37074838
Objective: No consensus exists on the ideal methodology to evaluate the economic impact and value of new, potentially curative gene therapies. We aimed to identify and describe published methodologic recommendations...
9.
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
Dabbous O, Chachoua L, Aballea S, Sivignon M, Persson U, Petrou S, et al.
Adv Ther . 2022 Nov; 40(2):393-424. PMID: 36451072
Introduction: We sought to synthesize published empirical studies that elicited and characterized societal valuations of orphan drugs and the attributes that may drive different valuations for orphan drugs versus other...
10.
Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency
Garrison Jr L, Jiao B, Dabbous O
Value Health . 2022 Nov; 26(3):336-343. PMID: 36336584
Objectives: Conventional cost-effectiveness analysis (CEA) for the value-based pricing of new medicines largely ignores the implications of limited market exclusivity (ie, patent-protection periods plus any exclusivity granted by regulators). This...